Qlt Inc (QLTI) 4.15 $QLTI
Seven Fat Years Of Event-Driven Investing
Chris DeMuth Jr. - Seeking Alpha - Thu Feb 12, 3:43AM CST
Originally Published on November 28, 2014 Lessons from the Recent Years and Opportunities for the Years to Come Chris DeMuth Jr It's not given to human beings to have such talent that they can just know everything about everything all the time....
OSHC: 14.07 (-0.06), LORL: 71.94 (+0.15), PFN: 10.19 (+0.01), QLTI: 4.15 (unch), DTV: 87.51 (-0.32), GPT: 6.83 (+0.04), GCVRZ: 0.64 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 11:45AM CST
BAK: 9.02 (+0.03), DRD: 2.27 (+0.10), QLTI: 4.15 (unch), EXPR: 14.61 (+0.33), OIBR: 2.49 (+0.34), RLJE: 1.82 (unch), ASPS: 22.32 (+0.09), IGTE: 39.53 (+0.62), LEDS: 1.34 (-0.02), VLTC: 0.77 (-0.04), THTI: 1.01 (-0.09), INWK: 6.29 (+0.69), GTE: 2.83 (+0.08), MHR: 2.62 (+0.11), ALDX: 11.01 (-0.25), BONT: 5.79 (+0.04), CNET: 1.58 (+0.02), SWHC: 12.63 (-0.20), OUTR: 68.39 (+2.22)
QLT Up 12.0%, Shares Break Through Resistance (QLTI)
Comtex SmarTrend(R) - Tue Jan 20, 10:38AM CST
QLT (NASDAQ:QLTI) is one of today's best performing low-priced stocks, up 12.0% to $4.58 on 1.0x average daily volume. Thus far today, QLT has traded 309,000 shares, vs. average volume of 307,000 shares per day. The stock has outperformed the Dow (12.0% to the Dow's -0.6%) and outperformed the S&P 500 (12.0% to the S&P's -0.3%) during today's trading.
QLTI: 4.15 (unch)
QLT to Appoint Glen Ibbott as Interim Chief Financial Officer
GlobeNewswire - Mon Jan 05, 6:23AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that Mr. Glen Ibbott has been appointed as the Interim Chief Financial Officer of the Company effective January 26, 2015, the resignation date of the Company's current Chief Financial Officer. In order to efficiently transition to the role of the Interim Chief Financial Officer, Mr. Ibbott has been appointed Vice President, Finance of the Company effective today.
QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 30, 5:31PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 22.50 (+0.15), NEON: 2.98 (+0.16), ADXS: 7.18 (+0.06), QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03), BRID: 7.55 (-0.04), XGTI: 0.43 (+0.01), WVFC: 11.02 (-0.45), BGMD: 0.88 (unch), SEED: 1.38 (-0.02), UPI: 1.27 (unch), JST: 5.35 (+0.14), GCBC: 29.50 (unch), KFFB: 8.02 (-0.13), CJJD: 2.59 (-0.01), MGYR: 8.45 (+0.04)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
QLT Announces Results of Annual General Meeting of Shareholders
GlobeNewswire - Tue Dec 16, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is pleased to announce that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on December 15, 2014 (the "Meeting" .
QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
QLT synthetic retinoid comes up short in Phase 2 study
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:50AM CST
QLTI: 4.15 (unch)
QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision
GlobeNewswire - Fri Dec 05, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced results from its multi-center, Phase 2a clinical trial of repeated treatments of oral QLT091001 in adult subjects with early age-related macular degeneration (AMD) and impaired dark adaptation and/or impaired low luminance vision. The Company previously announced positive results from its Phase 1b clinical trials for QLT091001 in subjects with the rare inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).
QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
QLT Announces Departure of Chief Financial Officer
GlobeNewswire - Tue Dec 02, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" today announced that Sukhi Jagpal, Chief Financial Officer of the Company, has notified the Company that he is leaving to pursue other opportunities. Mr. Jagpal will continue in his current role through January 26, 2015. The Company will explore its options to fill the position.
QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
QLT (QLTI) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
QLT (QLTI) Is in Oversold Territory: What’s Next?
QLTI: 4.15 (unch)
QLT Looks Undervalued With Significant Upside
Cory Renauer - at Seeking Alpha - Thu Oct 30, 11:40AM CDT
QLTI: 4.15 (unch)
QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AUXL: 36.47 (-0.06), BMY: 60.04 (+0.56)
QLT beats by $0.02
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:22AM CDT
QLTI: 4.15 (unch)
QLT Announces Third Quarter 2014 Results
GlobeNewswire - Tue Oct 28, 6:15AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company" is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the third quarter ended September 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
Seven Fat Years Of Event-Driven Investing
Chris DeMuth Jr. - Seeking Alpha - Thu Feb 12, 3:43AM CST
Originally Published on November 28, 2014 Lessons from the Recent Years and Opportunities for the Years to Come Chris DeMuth Jr It's not given to human beings to have such talent that they can just know everything about everything all the time....
OSHC: 14.07 (-0.06), LORL: 71.94 (+0.15), PFN: 10.19 (+0.01), QLTI: 4.15 (unch), DTV: 87.51 (-0.32), GPT: 6.83 (+0.04), GCVRZ: 0.64 (-0.01)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 11:45AM CST
BAK: 9.02 (+0.03), DRD: 2.27 (+0.10), QLTI: 4.15 (unch), EXPR: 14.61 (+0.33), OIBR: 2.49 (+0.34), RLJE: 1.82 (unch), ASPS: 22.32 (+0.09), IGTE: 39.53 (+0.62), LEDS: 1.34 (-0.02), VLTC: 0.77 (-0.04), THTI: 1.01 (-0.09), INWK: 6.29 (+0.69), GTE: 2.83 (+0.08), MHR: 2.62 (+0.11), ALDX: 11.01 (-0.25), BONT: 5.79 (+0.04), CNET: 1.58 (+0.02), SWHC: 12.63 (-0.20), OUTR: 68.39 (+2.22)
QLT Up 12.0%, Shares Break Through Resistance (QLTI)
Comtex SmarTrend(R) - Tue Jan 20, 10:38AM CST
QLT (NASDAQ:QLTI) is one of today's best performing low-priced stocks, up 12.0% to $4.58 on 1.0x average daily volume. Thus far today, QLT has traded 309,000 shares, vs. average volume of 307,000 shares per day. The stock has outperformed the Dow (12.0% to the Dow's -0.6%) and outperformed the S&P 500 (12.0% to the S&P's -0.3%) during today's trading.
QLTI: 4.15 (unch)
QLT to Appoint Glen Ibbott as Interim Chief Financial Officer
GlobeNewswire - Mon Jan 05, 6:23AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that Mr. Glen Ibbott has been appointed as the Interim Chief Financial Officer of the Company effective January 26, 2015, the resignation date of the Company's current Chief Financial Officer. In order to efficiently transition to the role of the Interim Chief Financial Officer, Mr. Ibbott has been appointed Vice President, Finance of the Company effective today. QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
Nasdaq stocks posting largest volume increases
AP - Tue Dec 30, 5:31PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
LARK: 22.50 (+0.15), NEON: 2.98 (+0.16), ADXS: 7.18 (+0.06), QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03), BRID: 7.55 (-0.04), XGTI: 0.43 (+0.01), WVFC: 11.02 (-0.45), BGMD: 0.88 (unch), SEED: 1.38 (-0.02), UPI: 1.27 (unch), JST: 5.35 (+0.14), GCBC: 29.50 (unch), KFFB: 8.02 (-0.13), CJJD: 2.59 (-0.01), MGYR: 8.45 (+0.04)
Doug Loe: Canada Has Earned Its Spot In The Biotech All-Star Team Photo
Life Sciences Report - Seeking Alpha - Fri Dec 19, 9:53AM CST
Biotech investors in the United States who overlook investment opportunities across the borders are missing out on huge opportunities, says Douglas Loe, healthcare equity analyst with Euro Pacific Canada. In this interview with The Life Sciences...
BIIB: 391.66 (-0.45), VRX: 167.00 (-0.50), QLTI: 4.15 (unch), CTRX: 53.24 (+0.65), BCRX: 10.06 (-0.09), ACT: 285.37 (+3.71), MDT: 75.26 (+0.33), TKMR: 21.45 (-0.22), NEPT: 1.83 (+0.06), BSX: 14.98 (+0.24), AGN: 229.49 (+1.87), CMRX: 40.16 (+0.08), ALNY: 95.54 (+1.67), SRPT: 12.76 (+0.11), SHPG: 239.82 (+6.11), NLNK: 38.84 (+1.51), SNY: 49.42 (+0.82), MSLI: 1.96 (+0.08), NVCN: 9.08 (-0.17), CRME: 9.76 (-0.14), EBS: 28.76 (-0.12), GSK: 47.94 (+1.99), CELG: 115.88 (+0.16), GILD: 101.90 (+1.10), MRK: 58.81 (-0.07), NVDQ: 15.12 (+0.51), NVS: 102.20 (-0.17)
QLT Announces Results of Annual General Meeting of Shareholders
GlobeNewswire - Tue Dec 16, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
is pleased to announce that, on a vote by ballot, the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on December 15, 2014 (the "Meeting" . QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)
QLT synthetic retinoid comes up short in Phase 2 study
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:50AM CST
QLTI: 4.15 (unch)
QLT Announces Results From Proof-of-Concept Trial With Oral Synthetic cis-Retinoid (QLT091001) in Adult Subjects With Impaired Dark Adaptation and/or Impaired Low Luminance Vision
GlobeNewswire - Fri Dec 05, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced results from its multi-center, Phase 2a clinical trial of repeated treatments of oral QLT091001 in adult subjects with early age-related macular degeneration (AMD) and impaired dark adaptation and/or impaired low luminance vision. The Company previously announced positive results from its Phase 1b clinical trials for QLT091001 in subjects with the rare inherited retinal degenerative diseases, Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP). QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
QLT Announces Departure of Chief Financial Officer
GlobeNewswire - Tue Dec 02, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
today announced that Sukhi Jagpal, Chief Financial Officer of the Company, has notified the Company that he is leaving to pursue other opportunities. Mr. Jagpal will continue in his current role through January 26, 2015. The Company will explore its options to fill the position. QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
QLT (QLTI) Is in Oversold Territory: What's Next? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:44AM CST
QLT (QLTI) Is in Oversold Territory: What’s Next?
QLTI: 4.15 (unch)
QLT Looks Undervalued With Significant Upside
Cory Renauer - at Seeking Alpha - Thu Oct 30, 11:40AM CDT
QLTI: 4.15 (unch)
QLT (QLTI) Reports Narrower-than-Expected Q3 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:00AM CDT
QLT Inc. (QLTI) reported a third-quarter 2014 loss of 10 cents.
QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AUXL: 36.47 (-0.06), BMY: 60.04 (+0.56)
QLT beats by $0.02
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:22AM CDT
QLTI: 4.15 (unch)
QLT Announces Third Quarter 2014 Results
GlobeNewswire - Tue Oct 28, 6:15AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"
is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the third quarter ended September 30, 2014. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP. QLTI: 4.15 (unch), QLT.TO: 5.10 (-0.03)
